Barbesaclone Abbvie
Barbesaclone Abbvie Uses, Dosage, Side Effects, Food Interaction and all others data.
Barbesaclone Abbvie, a salt compound of propylhexedrine and phenobarbital, is a potent antiepileptic. By weight, barbexaclone is 40% propylhexedrine and 60% phenobarbital. While barbexaclone has sedative properties, propylhexedrine has psychostimulant properties intended to offset these sedative effects. Pharmacokinetic studies have demonstrated that the pharmacokinetics of phenobarbital given as barbexaclone are not affected by propylhexedrine. Several reports from Spanish and Italian literature suggest that barbexaclone is at least as effective as phenobarbital in adults and children, while being better tolerated and having less sedative properties. These reports were conducted in a small series of patients in the 1970s and 1980s, and have yet to be confirmed by larger controlled trials. Despite the lack of controlled trials, barbexaclone was used widely in Turkey until it was discontinued in 2009.
Barbesaclone Abbvie exists in 25mg and 100mg tablets. 100mg of barbexaclone is equivalent to 60mg of phenobarbital. With this difference in potency in mind, other pharmacokinetic considerations such as dose titration, daily dosing, and optimal plasma concentration can be considered the same as for the equivalent amount of phenobarbital.
There has been a case of barbexaclone abuse due to the amphetamine like properties of propylhexedrine, although the comparative abuse potential is much lower than amphetamine.
| Trade Name | Barbesaclone Abbvie |
| Generic | Barbexaclone |
| Barbexaclone Other Names | Barbexaclon, Barbexaclona, Barbexaclone, Barbexaclonum |
| Type | |
| Formula | C22H33N3O3 |
| Weight | Average: 387.524 Monoisotopic: 387.252191935 |
| Groups | Experimental |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | Italy |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Created for the treatment for epilepsy, with the intent of creating an antiepileptic with less sedative properties than phenobarbital.
How Barbesaclone Abbvie works
Phenobarbitol targets GABA receptors in the CNS. Propylhexedrine is a TAAR1 agonist.
Toxicity
Barbiturates are associated with congenital heart malformations, facial clefts, and other malformations. [5] There is no available data on the use of barbexaclone in pregnancy. One case of a 36 year old women who used barbexaclone 300mg/day and oxcarbezine 600mg/day for 2 years before the pregnancy and 10 weeks into pregnancy resulted in an uncomplicated delivery and normal physical, motor, and mental development at 24 months of age. [5]
Volume of Distribution
In mice, the volume of distribution was 0.78L/kg of phenobarbital, and 19.3L/kg for propylhexedrine, after i.v. administration. [3] High but unequal tissue accumulation of propylhexedrine was observed in mice: lung = kidney > liver = brain > spleen > heart > skeletal muscle. [3]
Elimination Route
After oral administration of barbexaclone in mice the maximum plasma levels of prophylhexedrine appeared after 4 minutes, and propylhexedrine was seen to penetrate the blood brain barrier rapidly. Bioavailability (AUC oral / AUC iv) = 0.37. [3] Phenobarbital was observed to reach the blood more slowly, and brain uptake was a slow process. Equilibrium concentrations with plasma reached after 30 minutes after i.v injection. [3]
Half Life
After IV administration in mice, levels of phenobarbital declined exponentially with a half life of 7.5h. [3] For propylhexedrine t0.5a = 0.31h and t0.5b = 2.5h.
Innovators Monograph
You find simplified version here Barbesaclone Abbvie
